NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Forecast, Price & News $1.27 +0.01 (+0.79%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.26▼$1.2950-Day Range$1.26▼$1.8252-Week Range$1.17▼$3.02Volume88,024 shsAverage Volume1.12 million shsMarket Capitalization$84.80 millionP/E RatioN/ADividend YieldN/APrice Target$2.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CytomX Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.75 Rating ScoreUpside/Downside88.7% Upside$2.40 Price TargetShort InterestBearish3.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment-0.24Based on 6 Articles This WeekInsider TradingSelling Shares$31,468 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.37) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector808th out of 976 stocksPharmaceutical Preparations Industry376th out of 453 stocks 2.9 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.40, CytomX Therapeutics has a forecasted upside of 88.7% from its current price of $1.27.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.32% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 2.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 1.0 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,468.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions51.11% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.37) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About CytomX Therapeutics (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comSean A. Mccarthy Sells 14,601 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) StockSeptember 7, 2023 | fool.comCytomX Therapeutics (NASDAQ: CTMX)September 28, 2023 | Chaikin Analytics (Ad)Something is Coming for America's Top StockThis stock has already doubled this year - but it could hurt your portfolio if you hold it much longer. Learn why here.September 5, 2023 | finance.yahoo.comCytomX Therapeutics to Present at Upcoming September Investor ConferencesAugust 28, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on CytomX Therapeutics (CTMX)August 25, 2023 | finance.yahoo.comCytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAugust 14, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Hold Rating on CytomX Therapeutics (CTMX)August 10, 2023 | finance.yahoo.comCytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual ConferenceSeptember 28, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 10, 2023 | markets.businessinsider.comBarclays Remains a Buy on CytomX Therapeutics (CTMX)August 9, 2023 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 9, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)August 9, 2023 | finance.yahoo.comCytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2023 | finance.yahoo.comCytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 8, 2023 | benzinga.comEarnings Preview For CytomX TherapeuticsAugust 1, 2023 | finance.yahoo.comCytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023July 20, 2023 | finanznachrichten.deCytomX Therapeutics Inc.: CytomX Therapeutics Announces New Employment Inducement GrantsJune 30, 2023 | msn.comWhy Is CytomX Therapeutics Stock Shooting Higher TodayJune 30, 2023 | markets.businessinsider.comCytomX Therapeutics (CTMX) Gets a Hold from Mizuho SecuritiesJune 30, 2023 | finance.yahoo.comCytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.June 8, 2023 | finance.yahoo.comCytomX Therapeutics (NASDAQ:CTMX) Is In A Good Position To Deliver On Growth PlansJune 1, 2023 | finance.yahoo.comCytomX Therapeutics to Present at the Jefferies Healthcare ConferenceMay 11, 2023 | finance.yahoo.comCytomX Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 10, 2023 | finance.yahoo.comQ1 2023 CytomX Therapeutics Inc Earnings CallMay 10, 2023 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Hold from Mizuho SecuritiesMay 9, 2023 | finance.yahoo.comCytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 5, 2023 | finance.yahoo.comCytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some InvestorsSee More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees116Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.40 High Stock Price Forecast$3.19 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+88.7%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,320,000.00 Net Margins-84.21% Pretax Margin-63.92% Return on Equity-666.28% Return on Assets-23.90% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual Sales$53.16 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value($1.30) per share Price / Book-0.98Miscellaneous Outstanding Shares66,770,000Free Float62,161,000Market Cap$84.80 million OptionableOptionable Beta0.65 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Sean A. McCarthy D.Phil. (Age 56)DPHIL, Chairman & CEO Comp: $1.03MMr. Lloyd A. Rowland Jr. (Age 66)J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. Comp: $608.72kMr. Jeffrey Landau B.S. (Age 45)M.B.A., Sr. VP, Head of Strategy & Chief Bus. Officer Comp: $581.68kMr. Christopher W. Ogden (Age 39)Sr. VP of Fin. and Accounting, Principal Financial Officer & Principal Accounting Officer Dr. Marcia P. Belvin Ph.D.Sr. VP & Chief Scientific OfficerDr. Chau Cheng M.B.A.Ph.D., VP of Investor Relations & Corp. CommunicationsMs. Danielle Olander-MoghadassianSr. VP & Chief HR OfficerMs. Leslie RobbinsSr. VP of Intellectual PropertyDr. Yu-Waye Chu M.D. (Age 55)Chief Medical Officer Ms. Dawn BensonSr. VP of Quality & Product ManufacturingMore ExecutivesKey CompetitorsOcuphire PharmaNASDAQ:OCUPIO BiotechNASDAQ:IOBTLumiraDxNASDAQ:LMDXVaccinexNASDAQ:VCNXLifeVantageNASDAQ:LFVNView All CompetitorsInsiders & InstitutionsSean A MccarthySold 14,601 sharesTotal: $18,981.30 ($1.30/share)Marcia BelvinSold 4,119 sharesTotal: $5,354.70 ($1.30/share)Lloyd A RowlandSold 5,486 sharesTotal: $7,131.80 ($1.30/share)Citadel Advisors LLCBought 3,000 shares on 8/15/2023Ownership: 0.000%Marshall Wace LLPSold 55,437 shares on 8/14/2023Ownership: 1.010%View All Insider TransactionsView All Institutional Transactions CTMX Stock - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CTMX shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price forecast for 2023? 4 brokerages have issued 12 month price targets for CytomX Therapeutics' shares. Their CTMX share price forecasts range from $2.00 to $3.19. On average, they predict the company's stock price to reach $2.40 in the next twelve months. This suggests a possible upside of 88.7% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2023? CytomX Therapeutics' stock was trading at $1.60 on January 1st, 2023. Since then, CTMX shares have decreased by 20.6% and is now trading at $1.27. View the best growth stocks for 2023 here. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.17. The biotechnology company earned $24.72 million during the quarter, compared to the consensus estimate of $17.38 million. CytomX Therapeutics had a negative net margin of 84.21% and a negative trailing twelve-month return on equity of 666.28%. What ETF holds CytomX Therapeutics' stock ? Formidable ETF holds 318,111 shares of CTMX stock, representing 1.80% of its portfolio. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.72%), Renaissance Technologies LLC (1.68%), Bronte Capital Management Pty Ltd. (1.39%), Marshall Wace LLP (1.01%), Congress Park Capital LLC (0.16%) and LPL Financial LLC (0.15%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland, Marcia Belvin and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $1.27. How much money does CytomX Therapeutics make? CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $84.80 million and generates $53.16 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does CytomX Therapeutics have? The company employs 116 workers across the globe. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353. This page (NASDAQ:CTMX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.